PTCy, Abatacept, and Tacrolimus for GVHD Prophylaxis
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic stem cell donors; however, the...
Baricitinib Plus Standard GVHD Prophylaxis: Phase 1 Results
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of...
The Lasting Impact of Surviving Severe aGVHD
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT) demonstrated greater risk...
Impact of Ruxolitinib Initiation Timing
Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to corticosteroids. Prolonged...
Pilot Data on Fecal Microbiotherapy for Acute GI GVHD
In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on...
PRMT5 Identified as Potential GVHD Treatment Target
Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was upregulated in acute graft-versus-host...
Ruxolitinib With Corticosteroids in Pediatric GVHD
In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence reported...
Belumosudil Significantly Affects IST Serum Concentrations
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved for the treatment of chronic...
Adding Itacitinib to Conventional GVHD Prophylaxis
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and efficacy...
A New Standard for Graft-Versus-Host Disease Prevention
For years, the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) has been a calcineurin...
Itacitinib Potentially Superior to Corticosteroids in GVHD
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy against...
Featured on DocWire
Curated Journal Abstracts
Advertisement